AKRO / 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease

Akero only has one drug in clinical trials. The company said the drug didn't meet its primary endpoint of slowing NASH. more_horizontal

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of more_horizontal

Stocks are higher in early trading on dovish commentary from Federal Reserve officials. Hyatt Hotels Corporation (H) shares jump as the company will b more_horizontal

Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty li more_horizontal

Akero's experimental NASH drug efruxifermin (EFX) missed its primary endpoint in a phase 2b study. However, statistically significant improvement was more_horizontal

Akero Therapeutics Inc (NASDAQ:AKRO) is plummeting to 52-week lows, after its treatment for severe fatty liver disease, efruxifermin, missed its main more_horizontal

Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate more_horizontal

Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the resul more_horizontal